Eli Lilly and Company (NYSE:LLY) Shares Sold by Cullen Investment Group LTD.

Cullen Investment Group LTD. lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.1% in the first quarter, Holdings Channel.com reports. The firm owned 12,673 shares of the company’s stock after selling 142 shares during the period. Eli Lilly and Company comprises 1.6% of Cullen Investment Group LTD.’s portfolio, making the stock its 15th largest holding. Cullen Investment Group LTD.’s holdings in Eli Lilly and Company were worth $10,467,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. FPC Investment Advisory Inc. grew its stake in Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after purchasing an additional 43 shares in the last quarter. Mascagni Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $43,000. Prudent Man Investment Management Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $48,000. Compass Financial Services Inc acquired a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $50,000. Finally, Fiduciary Advisors Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $58,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Performance

LLY stock opened at $718.59 on Thursday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market capitalization of $681.03 billion, a price-to-earnings ratio of 61.37, a PEG ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The stock’s fifty day moving average is $782.03 and its two-hundred day moving average is $801.29.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.58 earnings per share. On average, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.83%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company’s payout ratio is 48.82%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Truist Financial increased their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Hsbc Global Res downgraded Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. The Goldman Sachs Group raised Eli Lilly and Company from a “neutral” rating to a “buy” rating and reduced their target price for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, Guggenheim reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Friday, May 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.